487 related articles for article (PubMed ID: 29998598)
1. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
2. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.
Szaflarski JP; Devinsky O; Lopez M; Park YD; Zentil PP; Patel AD; Thiele EA; Wechsler RT; Checketts D; Sahebkar F
Epilepsia; 2023 Mar; 64(3):619-629. PubMed ID: 36537757
[TBL] [Abstract][Full Text] [Related]
5. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
9. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program.
Flamini RJ; Comi AM; Bebin EM; Chez MG; Clark G; Devinsky O; Hussain SA; Lyons PD; Patel AD; Rosengard JL; Sahebkar F; Segal E; Seltzer L; Szaflarski JP; Weinstock A
Epilepsia; 2023 Aug; 64(8):e156-e163. PubMed ID: 37243404
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial.
Scheffer IE; Hulihan J; Messenheimer J; Ali S; Keenan N; Griesser J; Gutterman DL; Sebree T; Sadleir LG
JAMA Netw Open; 2021 Sep; 4(9):e2123930. PubMed ID: 34477852
[TBL] [Abstract][Full Text] [Related]
14. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
15. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
16. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Devinsky O; Verducci C; Thiele EA; Laux LC; Patel AD; Filloux F; Szaflarski JP; Wilfong A; Clark GD; Park YD; Seltzer LE; Bebin EM; Flamini R; Wechsler RT; Friedman D
Epilepsy Behav; 2018 Sep; 86():131-137. PubMed ID: 30006259
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C
Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695
[TBL] [Abstract][Full Text] [Related]
18. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.
Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O
Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
